› Forums › General Melanoma Community › best treatment for liver mets
- This topic has 8 replies, 3 voices, and was last updated 13 years, 9 months ago by
LynnLuc.
- Post
-
- January 18, 2011 at 2:57 pm
I have some new liver mets and was wondering what are the most effective treatments for liver mets. I do not think they are good candidates for surgical removal, it is more multiple areas of uptake spread throughout the liver.
Any ideas?
I have some new liver mets and was wondering what are the most effective treatments for liver mets. I do not think they are good candidates for surgical removal, it is more multiple areas of uptake spread throughout the liver.
Any ideas?
- Replies
-
-
- January 18, 2011 at 5:31 pm
Delcath is actively enrolling patients in a Phase III clinical trial testing its proprietary drug delivery system, known as Percutaneous Hepatic Perfusion (“PHP”), with melphalan for the treatment of ocular and cutaneous melanoma metastatic to the liver.
This NCI-led trial is enrolling patients at leading cancer centers throughout the United States. Commenting on these orphan-drug designations, Richard L. Taney, President and CEO of Delcath, stated, “These favorable designations are important steps in our efforts to secure Delcath’s commercial position upon conclusion of our pivotal Phase III trial for metastatic melanoma. We remain steadfast in our commitment to become the leader in the regional treatment of liver cancers and we continue to enroll patients in this study, and advance our technology and the promise that it offers to patients with these deadly forms of melanoma and other cancers of the liver, all with limited treatment options.”
Orphan drug designation, when granted by the FDA’s Office of Orphan Products Development, allows for up to seven years of market exclusivity upon FDA approval, as well as clinical study incentives, study design assistance, waivers of certain FDA user fees, and potential tax credits.
James F. Pingpank, Jr., MD, FACS
Associate Professor of Surgery
Division of Surgical Oncology
Suite 406, UPMC Cancer Pavillion
5150 Centre Avenue
Pittsburgh, PA 15232
412-692-2852 (Office)
412-692-2520 (Fax)
[email protected]
-
- January 20, 2011 at 7:43 pm
I have had multiple systemic treatments and am in search of treatment of liver mets Checked the clinical trial website and there are no open trials. Contacted Delcath directly and confirmed they have completed their trials and waiting for FDA (the black hole) approval. They also said Delcath PHP is not available on a "compassionate" or "expanded use" basis.
If anyone has any other information or suggestions, please let me know.
Xena
-
- January 20, 2011 at 7:43 pm
I have had multiple systemic treatments and am in search of treatment of liver mets Checked the clinical trial website and there are no open trials. Contacted Delcath directly and confirmed they have completed their trials and waiting for FDA (the black hole) approval. They also said Delcath PHP is not available on a "compassionate" or "expanded use" basis.
If anyone has any other information or suggestions, please let me know.
Xena
-
- January 18, 2011 at 5:31 pm
Delcath is actively enrolling patients in a Phase III clinical trial testing its proprietary drug delivery system, known as Percutaneous Hepatic Perfusion (“PHP”), with melphalan for the treatment of ocular and cutaneous melanoma metastatic to the liver.
This NCI-led trial is enrolling patients at leading cancer centers throughout the United States. Commenting on these orphan-drug designations, Richard L. Taney, President and CEO of Delcath, stated, “These favorable designations are important steps in our efforts to secure Delcath’s commercial position upon conclusion of our pivotal Phase III trial for metastatic melanoma. We remain steadfast in our commitment to become the leader in the regional treatment of liver cancers and we continue to enroll patients in this study, and advance our technology and the promise that it offers to patients with these deadly forms of melanoma and other cancers of the liver, all with limited treatment options.”
Orphan drug designation, when granted by the FDA’s Office of Orphan Products Development, allows for up to seven years of market exclusivity upon FDA approval, as well as clinical study incentives, study design assistance, waivers of certain FDA user fees, and potential tax credits.
James F. Pingpank, Jr., MD, FACS
Associate Professor of Surgery
Division of Surgical Oncology
Suite 406, UPMC Cancer Pavillion
5150 Centre Avenue
Pittsburgh, PA 15232
412-692-2852 (Office)
412-692-2520 (Fax)
[email protected]
-
- January 18, 2011 at 7:33 pm
An interesting article on this http://www.sciencedaily.com/releases/2010/06/100606104823.htm
-
- January 18, 2011 at 7:33 pm
An interesting article on this http://www.sciencedaily.com/releases/2010/06/100606104823.htm
-
- January 21, 2011 at 4:49 am
Have you considered a trial like this? Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma .
MDX-1106 is the Anti-PD-1 and has show great results in kidney cancer and other solid tumors. It is also part of my vaccine trial.
Good luck and blessings!
-
- January 21, 2011 at 4:49 am
Have you considered a trial like this? Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma .
MDX-1106 is the Anti-PD-1 and has show great results in kidney cancer and other solid tumors. It is also part of my vaccine trial.
Good luck and blessings!
-
- You must be logged in to reply to this topic.